Qualitative study on the cognition of CAR T cell therapy in patients with hematologic malignancy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2200058273

Enrollment

Unknown

Registered

2022-04-04

Start date

2022-03-30

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancy

Interventions

Case series:N/A

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Received at least one CAR T cell infusion during hospitalization; 2. Patients make clear their own disease diagnosis; 3. Aged >= 18 years; 4. Basic language communication skills.

Exclusion criteria

Exclusion criteria: 1. Serious impairment of speech, vision and hearing due to complications or complications; 2. Patients suffering from serious infectious diseases, viral diseases, autoimmune diseases or other diseases such as diabetes before treatment; 3. Patients with a history of mental illness; 4. Treatment decisions are made by the family.

Design outcomes

Primary

Measure	Time frame
Understanding of CAR T cell therapy;	—

Countries

China

Contacts

Public ContactDing Shuyi

The First Affiliated Hospital, School of Medicine, Zhejiang University

1709025@zju.edu.cn+86 13735499761

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026